Receptor variants and the development of centrally acting medications .

Stuart A Neale, Kumiko Kambara, Thomas E Salt, Daniel Bertrand

Open access · diamondAbstract read

In one paragraph

Article in Dialogues in clinical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 86% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Stuart A NealeNeurexpert Limited, The Core, Science Central, Newcastle Upon Tyne, UK.

Kumiko KambaraHiQScreen Sàrl, Geneva, Switzerland.

Thomas E SaltNeurexpert Limited, The Core, Science Central, Newcastle Upon Tyne, UK; Honorary Professor, University of Newcastle, Newcastle, UK.

Daniel BertrandHiQScreen Sàrl, Geneva, Switzerland; Emeritus Professor, Medical Faculty, Geneva, Switzerland.

HiQScreen (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progressive changes in research paradigms observed in the largest pharmaceutical companies and the burgeoning of biotechnology startups over the last 10 years have generated a need for outsourcing research facilities. In parallel, progress made in the fields of genomics, protein expression in recombinant systems, and electrophysiological recording methods have offered new possibilities for the development of contract research organizations (CROs). Successful partnering between pharmaceutical companies and CROs largely depends upon the competences and scientific quality on offer for the discovery of novel active molecules and targets. Thus, it is critical to review the knowledge in the field of neuroscience research, how genetic approaches are augmenting our knowledge, and how they can be applied in the translation from the identification of potential molecules up to the first clinical trials. Taking these together, it is apparent that CROs have an important role to play in the neuroscience of drug discovery. .

Indexed as

Central Nervous System AgentsContract ServicesDrug DevelopmentDrug DiscoveryGenomicsHumansMental DisordersNeurosciencesReceptors, Cell SurfaceCentral Nervous System AgentsReceptors, Cell Surfacecentral nervous systemcontract research organizationdrug discoveryelectrophysiologypharmacology

Identifiers

PMID31636489

PMCPMC6787545

OpenAlexW3010474478

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.